Scholar Rock
Preço: 44.18Empresa e modelo de negócios
Scholar Rock is a biotechnology company focused on developing innovative therapies for serious diseases. Its core products include treatments targeting muscle disorders and other conditions related to growth factor signaling. The company primarily generates revenue through research and development collaborations and potential future product sales. Scholar Rock's major business segments involve drug discovery and clinical development, with a focus on advancing its pipeline of therapeutic candidates.
Perfil de investimento
The investment profile of Scholar Rock is more aligned with growth investors due to its focus on developing novel therapies and the potential for significant future revenue from product commercialization. However, the high risk associated with its current financial performance and lack of profitability may deter conservative investors. The stock may appeal to those with a longer investment horizon who are willing to accept volatility for potential future gains.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- -3.45 Risco
- Surpresa de EPS
- -1.2% em linha
- Volatilidade 20d
- 3.0% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-06-09 02:52 | Manter | Vender | Weak fundamentals and negative momentum raise significant concerns. |
| 2026-06-01 02:51 | Vender | Manter | Weak fundamentals and high risk limit upside potential. |
| 2026-05-08 15:06 | — | Vender | Weak fundamentals and high risk overshadow potential upside. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-05-08 10:35 | Barclays | Preço-alvo elevado | 53 → 55 | 46.45 |
| 2026-05-08 10:22 | H.C. Wainwright | Preço-alvo elevado | 58 → 65 | 46.45 |
| 2026-04-20 20:21 | Canaccord Genuity | Atualizar | — → 62 | 47.8 |
Nada ainda